Suppr超能文献

mTORC1 促进肝癌中 ARID1A 的降解和致癌性染色质重塑。

mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.

机构信息

Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.

State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.

出版信息

Cancer Res. 2021 Nov 15;81(22):5652-5665. doi: 10.1158/0008-5472.CAN-21-0206. Epub 2021 Aug 24.

Abstract

The SWI/SNF chromatin remodeling complexes control accessibility of chromatin to transcriptional and coregulatory machineries. Chromatin remodeling plays important roles in normal physiology and diseases, particularly cancer. The ARID1A-containing SWI/SNF complex is commonly mutated and thought to be a key tumor suppressor in hepatocellular carcinoma (HCC), but its regulation in response to oncogenic signals remains poorly understood. mTOR is a conserved central controller of cell growth and an oncogenic driver of HCC. Remarkably, cancer mutations in mTOR and SWI/SNF complex are mutually exclusive in human HCC tumors, suggesting that they share a common oncogenic function. Here, we report that mTOR complex 1 (mTORC1) interact with ARID1A and regulates ubiquitination and proteasomal degradation of ARID1A protein. The mTORC1-ARID1A axis promoted oncogenic chromatin remodeling and YAP-dependent transcription, thereby enhancing liver cancer cell growth and tumor development . Conversely, excessive ARID1A expression counteracted AKT-driven liver tumorigenesis . Moreover, dysregulation of this axis conferred resistance to mTOR-targeted therapies. These findings demonstrate that the ARID1A-SWI/SNF complex is a regulatory target for oncogenic mTOR signaling, which is important for mTORC1-driven hepatocarcinogenesis, with implications for therapeutic interventions in HCC. SIGNIFICANCE: mTOR promotes oncogenic chromatin remodeling by controlling ARID1A degradation, which is important for liver tumorigenesis and response to mTOR- and YAP-targeted therapies in hepatocellular carcinoma..

摘要

SWI/SNF 染色质重塑复合物控制染色质对转录和共调控机制的可及性。染色质重塑在正常生理和疾病中发挥着重要作用,尤其是癌症。含有 ARID1A 的 SWI/SNF 复合物通常发生突变,被认为是肝细胞癌 (HCC) 中的关键肿瘤抑制因子,但它对致癌信号的反应调节仍知之甚少。mTOR 是细胞生长的保守中央控制器,也是 HCC 的致癌驱动因子。值得注意的是,人类 HCC 肿瘤中 mTOR 和 SWI/SNF 复合物的癌症突变是相互排斥的,这表明它们具有共同的致癌功能。在这里,我们报告 mTOR 复合物 1 (mTORC1) 与 ARID1A 相互作用,并调节 ARID1A 蛋白的泛素化和蛋白酶体降解。mTORC1-ARID1A 轴促进致癌染色质重塑和 YAP 依赖性转录,从而增强肝癌细胞的生长和肿瘤发展。相反,过量的 ARID1A 表达会抵消 AKT 驱动的肝肿瘤发生。此外,该轴的失调导致对 mTOR 靶向治疗的耐药性。这些发现表明,ARID1A-SWI/SNF 复合物是致癌 mTOR 信号的调节靶点,对于 mTORC1 驱动的肝癌发生具有重要意义,并对 HCC 的治疗干预具有重要意义。意义:mTOR 通过控制 ARID1A 的降解来促进致癌性染色质重塑,这对于肝肿瘤发生以及对肝细胞癌中 mTOR 和 YAP 靶向治疗的反应很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e91/8595749/78b6713cdfa4/nihms-1735935-f0001.jpg

相似文献

8
PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma.PELP1 是肝细胞癌的一个新的治疗靶点。
Cancer Res Commun. 2024 Oct 1;4(10):2610-2620. doi: 10.1158/2767-9764.CRC-24-0173.

引用本文的文献

5
ARID1A and Its Impact Across the Hallmarks of Cancer.ARID1A及其对癌症各特征的影响。
Int J Mol Sci. 2025 May 13;26(10):4644. doi: 10.3390/ijms26104644.

本文引用的文献

2
Pan-cancer analysis of whole genomes.泛癌症全基因组分析。
Nature. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5.
4
7
Chromatin remodeling in mammalian embryos.哺乳动物胚胎中的染色质重塑。
Reproduction. 2018 Mar;155(3):R147-R158. doi: 10.1530/REP-17-0488. Epub 2018 Jan 16.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验